Rhythm Pharmaceuticals stock hits all-time high at 99.13 USD

Rhythm Pharmaceuticals (NASDAQ:RYTM) Inc. stock reached a significant milestone, hitting an all-time high of 99.13 USD. The company, now valued at $6.55 billion, boasts impressive gross profit margins of 89% and has delivered strong revenue growth of 54% over the last twelve months. According to InvestingPro analysis, the stock appears to be trading above its Fair Value. This achievement marks a notable period of growth for the biotechnology company, which has experienced a remarkable 123.35% increase in its stock value over the past year. The surge reflects investor confidence and positive market sentiment surrounding the company’s innovative approaches in the pharmaceutical sector. As Rhythm Pharmaceuticals continues to advance its pipeline and strategic initiatives, the stock’s performance underscores the robust interest and optimism among stakeholders. InvestingPro subscribers have access to 14 additional expert tips and a comprehensive Pro Research Report, offering deeper insights into the company’s valuation and growth prospects.

In other recent news, Rhythm Pharmaceuticals reported impressive financial results for the second quarter of 2025, with global sales of IMCIVREE reaching $48.5 million. This figure marks a 29% increase from the previous quarter and surpassed the forecasts of analysts, including those from H.C. Wainwright and TD Cowen. In regulatory developments, the U.S. Food and Drug Administration has accepted Rhythm Pharmaceuticals’ supplemental New Drug Application for setmelanotide, aimed at treating acquired hypothalamic obesity, with a priority review decision expected by December 20, 2025. Similarly, the European Medicines Agency has begun reviewing the company’s Type II variation submission for the same indication. Analyst firms have responded positively to these developments, with Citizens JMP raising its price target for Rhythm Pharmaceuticals to $135 and maintaining a Market Outperform rating. H.C. Wainwright also increased its price target from $80 to $100, maintaining a Buy rating on the stock. TD Cowen followed suit, raising its price target to $110 from $85, citing the strong revenue performance. These recent developments highlight the company’s ongoing growth and regulatory progress in expanding its market opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.